Date Analyst Coverage x
05/10/2021 Pitt Street Research Pitt Street Research – Cellmid Initiation Report
06/11/2019 Small Cap Insider National Priceline Agreement
02/10/2019 Small Cap Insider New Signed Distribution Agreements
30/08/2019 Small Cap Insider Trending towards break even
29/05/2019 Small Cap Insider New experienced midkine CEO appointment
13/09/2018 Blue Ocean Equities Cellmid Limited Growth Trifecta. New Geographies. New Channels. New Products
24/01/2017 Next Biotech CDY Backs Hair Raising Growth for 2017 as it Capitalises on US Entry
16/11/2016 Lodge Partners Research Hair growth equals sales growth equals share price growth
10/10/2016 Switzer Super Report Top commentator James Dunn from Switzer report rates CDY as a very interesting buy
27/06/2016 Van Leeuwenhoeck Research Cellmid Valuation at AUD 0.086 per share
14/09/2015 Van Leeuwenhoeck Research Cellmid Limited: Revenue stage biotech with strong pipeline
24/11/2014 Baillieu Holst Research It’s rare for one company to own a whole new target this big
13/06/2014 Baillieu Holst Research Australian Life Sciences
30/05/2014 Baillieu Holst Research It’s rare for a company to own a whole new target this big
03/02/2014 Baillieu Holst Research and RM Research First-in-Class mAb Oncology Program Will Rerate the Stock; Lots of Room to Grow for Advangen; New Target Price of 8.4c
11/03/2013 RM Research Strong Investment Thesis Going Forward: Multiple Catalysts and Upside Opportunities – A Rare Find
15/10/2012 RM Research Initiating Coverage
01/05/2011 Vista Partners Initiates coverage on Cellmid Limited; AUD $0.10 Target Price…
01/11/2010 Validated cancer diagnostic kit gives potential to enter US$45bn market…
18/04/2010 A pivotal year for Cellmid…
18/10/2009 Looking to profit from large IP portfolio…
15/05/2009 Targeting the early detection of cancer…
Shop évolis®